Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy A Cohort Study
Top Cited Papers
- 5 October 2020
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 173 (7), 536-+
- https://doi.org/10.7326/M20-3689
Abstract
Background: The incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving anti-retroviral therapy (ART) have not been characterized in large populations. Objective: To describe the incidence and severity of COVID-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART. Design: Cohort study. Setting: HIV clinics in 60 Spanish hospitals between 1 February and 15 April 2020. Participants: 77 590 HIV-positive persons receiving ART. Measurements: Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs for polymerase chain reaction-confirmed COVID-19 diagnosis, hospitalization, intensive care unit (ICU) admission, and death. Risk and 95% CIs for COVID-19 diagnosis and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafen-amide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated through Poisson regression models. Results: Of 77 590 HIV-positive persons receiving ART, 236 were diagnosed with COVID-19, 151 were hospitalized, 15 were admitted to the ICU, and 20 died. The risks for COVID-19 diag-nosis and hospitalization were greater in men and persons older than 70 years. The risk for COVID-19 hospitalization was 20.3 (95% CI, 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving ABC/3TC, and 20.0 (CI, 14.2 to 27.3) for those receiving other regimens. The corresponding risks for COVID-19 diagnosis were 39.1 (CI, 31.8 to 47.6), 16.9 (CI, 10.5 to 25.9), 28.3 (CI, 21.5 to 36.7), and 29.7 (CI, 22.6 to 38.4), respectively. No patient receiving TDF/FTC was admitted to the ICU or died. Limitation: Residual confounding by comorbid conditions cannot be completely excluded. Conclusion: HIV-positive patients receiving TDF/FTC have a lower risk for COVID-19 and related hospitalization than those receiving other therapies. These findings warrant further investigation in HIV preexposure prophylaxis studies and randomized trials in persons without HIV.Keywords
This publication has 34 references indexed in Scilit:
- Differential effects of acyclic nucleoside phosphonates on nitric oxide and cytokines in rat hepatocytes and macrophagesInternational Immunopharmacology, 2012
- Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 TransmissionScience Translational Medicine, 2011
- Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12/IL-10 Balance in Human Primary CellsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- HIV Infection, Inflammation, Immunosenescence, and AgingAnnual Review of Medicine, 2011
- Measurement of antiretroviral drugs in the lungs of HIV-infected patientsHIV Therapy, 2010
- Early Immune Senescence in HIV DiseaseCurrent HIV/AIDS Reports, 2010
- Antiretroviral Tissue Kinetics: In Vivo Imaging Using Positron Emission TomographyAntimicrobial Agents and Chemotherapy, 2009
- Consideration of Highly Active Antiretroviral Therapy in the Prevention and Treatment of Severe Acute Respiratory SyndromeClinical Infectious Diseases, 2004
- Immunobiological activity of N-[2-(phosphonomethoxy)alkyl] derivatives of N6-substituted adenines, and 2,6-diaminopurinesEuropean Journal of Pharmacology, 2003
- Activation by 9-(R)-[2-(Phosphonomethoxy)Propyl]Adenine of Chemokine (RANTES, Macrophage Inflammatory Protein 1α) and Cytokine (Tumor Necrosis Factor Alpha, Interleukin-10 [IL-10], IL-1β) ProductionAntimicrobial Agents and Chemotherapy, 2001